ADAURA
In completely resected EGFR-mutated stage IB–IIIA NSCLC, does adjuvant osimertinib improve disease-free and overall survival versus placebo?
Trial design and population
Key results
At 5 years, OS was 88% with osimertinib vs 78% with placebo (HR 0.49, 95.03% CI 0.33–0.73; P<.001). Four-year DFS was 73% vs 38% (HR 0.23, 95% CI 0.18–0.30).
Source-reported outcome visualization
5-year overall survival · 5 years
Bars are scaled to the larger reported group value; endpoint, unit and horizon are labelled. Values are source-reported, not estimated from medians.
Absolute Effect
Absolute 5-year OS gain 10 percentage points; NNT 10 based on 5-year OS. Four-year DFS gain 35 points; NNT 3 based on 4-year DFS.
NNT: 10 (5-year OS); 3 (5-year DFS). Use only at the stated endpoint/time horizon; median survival differences are not converted into NNT.
NNH: Not quantifiable. Common effects include diarrhoea, paronychia and rash; uncommon but important risks include interstitial lung disease, QT prolongation and cardiomyopathy. NNH not quantifiable from a single selected fixed-time excess-harm endpoint.
Time-to-event hazard ratios and median survival are not treated as absolute risk differences. Where no defensible fixed-time NNT/NNH is available, the source-reported endpoint is visualized instead.
Safety and treatment burden
Common effects include diarrhoea, paronychia and rash; uncommon but important risks include interstitial lung disease, QT prolongation and cardiomyopathy. NNH not quantifiable from a single selected fixed-time excess-harm endpoint.
Follow-up, maturity and limitations
Follow-up: Updated 5-year analysis.
Applies to EGFR exon 19 deletion/L858R tumours after complete resection; do not extrapolate to uncommon EGFR variants. DFS and OS reflect the adjuvant strategy with chemotherapy permitted.
Clinical interpretation
Current-practice context · reviewed 20 October 2026
This page separates the original trial findings from contemporary treatment sequencing. Confirm current guidelines, local regulatory status, biomarker requirements, prior treatment exposure and patient-specific contraindications before applying the evidence. Historical comparators may no longer represent the current standard; subgroup findings and immature endpoints are labelled rather than generalized.